durvalumab + pazopanib

The combination of durvalumab and pazopanib is an investigational treatment that has shown promising results in patients with advanced soft tissue sarcomas (STS). ## Mechanism of Action Durvalumab is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and its receptors, enhancing T cell function in the tumor microenvironment[9]. This helps restore the immune system's ability to recognize and attack cancer cells. Pazopanib is a multi-targeted tyrosine kinase inhibitor that primarily works through its antiangiogenic properties. It inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and c-kit[6]. By blocking these pathways, pazopanib limits tumor growth by preventing the formation of new blood vessels that supply tumors with nutrients and oxygen. The rationale behind combining these agents is based on the central role played by VEGFR in immunosuppression, suggesting potential synergistic effects when combining VEGFR inhibition with immune checkpoint blockade[2]. ## Clinical Development The combination has been evaluated in a single-arm, phase 2 clinical trial (NCT03798106) in patients with metastatic or locally advanced soft tissue sarcoma[1][2][3]. In this trial: - Treatment consisted of pazopanib 800 mg orally once daily and durvalumab 1500 mg administered intravenously once every 3 weeks[1][5] - The primary endpoint was overall response rate (ORR)[1] - The trial met its pre-specified endpoint with an ORR of 30.4%[1] - Median progression-free survival was 7.7 months (95% confidence interval: 5.7-10.4)[1][5] - The combination showed particularly promising activity in certain STS subtypes, including alveolar soft-part sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, and desmoplastic small round cell tumors[5] ## Safety Profile The combination demonstrated a manageable toxicity profile. Common treatment-related adverse events of grades 3-4 included: - Neutropenia (19.1%)[1][5] - Elevated aspartate aminotransferase (14.9%)[1][5] - Elevated alanine aminotransferase (10.6%)[1][5] - Thrombocytopenia (8.5%)[1][5] Other common adverse events of any grade included fatigue (42.6%), anorexia (36.2%), and diarrhea (36.2%)[2].